Novartis CAR-T Cell Therapy Receives FDA Breakthrough Designation – Pharmaceutical Processing
Pharmaceutical Processing |
Novartis CAR–T Cell Therapy Receives FDA Breakthrough Designation
Pharmaceutical Processing Novartis announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and … Novartis advances with push on cancer and liver disease |
